Trinity Partners to Present and Release New Whitepaper at ISPOR Annual Meeting

Whitepaper analyzes what the most expensive recent drug launches reveal about what our society values and is willing to pay for

BOSTON--(BUSINESS WIRE)--Trinity Partners, a global life sciences consulting firm, announced today that it will participate in the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22^nd Annual International Meeting, being held in Boston on May 20-24.

This year’s ISPOR meeting draws healthcare stakeholders with an interest in health economics and outcomes research (HEOR), including policy makers, payers, thought leaders, researchers, academicians, decision makers and patient representatives. The May meeting will focus on significant changes in drug development and regulatory decision making with the timely theme, ‘Evidence and Value in a Time of Social and Policy Change.’

“The healthcare industry is transforming. With a sharper lens on drug pricing, manufacturers must ensure they effectively demonstrate, with supporting evidence, the value their product provides,” said Jillian Godfrey Scaife, Principal, Trinity Partners. “We are thrilled to attend ISPOR and showcase our work with clients who are focused on providing innovative, life-changing therapies to patients.”

In tandem with the annual meeting, Trinity will announce the findings of a whitepaper titled, “What We Value: The Proposition Behind the Price.” The authors analyze the most costly drugs to the healthcare system that were approved by the FDA from 2014-2016 in order to understand the interaction between value and price. In its latest industry analysis, Trinity will reveal what factors appear to allow some drugs a higher price point than others and will also address other key questions, including: What do the most expensive drug launches in the recent past reveal about what our society values? What does the market seem to be willing to pay for? To download the full whitepaper, please click here: http://bit.ly/2rvnShU

Additionally, Trinity experts will participate in three poster presentations at ISPOR:

• Epidemiology of Metastatic Melanoma and Frequency of Mutation Testing in the U.S. Medicare Population (May 22, 3:30 p.m. – 7:45 p.m.) Presented by Trinity’s Maxim Sheinin, Zahra Al-Khateeb, Maria Isabella Kredlow, Kevin Francis, Nandini Hadker and Herman Sanchez, along with Ira Steinberg, Vice President, Medical Affairs at Array BioPharma.
• Patient and Physician Preferences in Selecting a Biologic for Moderate-to-Severe Crohn’s Disease (May 23, 8:30 a.m. – 2:00 p.m.) Presented by Trinity’s Amod Athavale, Aparna Deshpande, Gordon Lau and Nandini Hadker, along with Janssen Scientific Affairs’ Erik Muser and Mike Ingham.
• Measuring the Impact of Geriatric Care Among Medicare Beneficiaries (May 23, 3:45 p.m. – 7:45 p.m.) Presented by Trinity’s Gavin Miyasato, Fotios Kokkotos, PhD, PSTAT, Zheng Wang, and Marissa Suh, along with researchers from Boston University.

For more information on Trinity Partners, please visit http://www.trinitypartners.com/ or follow Trinity on Twitter: https://twitter.com/TrinityLifeSci.

About Trinity Partners
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here.